Skip to main content Skip to main menu
UF Health University of Florida
Department of Neurology College of Medicine - Jacksonville
Request an Appointment
Suparna R Krishnaiengar

Suparna R Krishnaiengar, M.D.

Associate Professor; Associate Program Director, Neurology Residency

Department: Neurology – Jacksonville
Business Email: suparna.krishnaiengar@jax.ufl.edu

On This Page

About Suparna R Krishnaiengar

Suparna Krishnaiengar, M.D., is a University of Florida assistant professor of neurology and a neurologist at the UF Health Neuroscience Institute in Jacksonville specializing in clinical neurophysiology and epilepsy. She also serves as associate program director for the Neurology Residency Program.

Dr. Krishnaiengar received her medical degree from the University of Mysore in Mysore, India. She completed residency training in neurology, as well as a fellowship in clinical neurophysiology, at Oklahoma University Health Sciences Center in Oklahoma City, Oklahoma. She also completed a fellowship in clinical neurophysiology, electroencephalography and epilepsy at the Cleveland Clinic Foundation in Cleveland, Ohio. Dr. Krishnaiengar is board-certified in neurology, clinical neurophysiology and epilepsy.

Additional Positions:
Associate Program Director
2017 – Current · Neurology Residency
Associate Professor of Neurology
2011 – Current · University of Florida

Accomplishments

  1. Exemplary Teacher Award

    University of Florida College of Medicine – Jacksonville

Teaching Profile

Courses Taught

  1. MDC7800 – Neurology Clerkship

    College of Medicine

Board Certifications

  • Clinical Neurophysiology
    American Board of Psychiatry and Neurology
  • Epilepsy
    American Board of Psychiatry and Neurology
  • Neurology
    American Board of Psychiatry and Neurology

Clinical Profile

Specialties

  • Neurology

Subspecialties

  • Clinical Neurophysiology
  • Epilepsy

Publications

Academic Articles

  1. Lance Adams Syndrome in the Setting of COVID-19 Pneumonia.

    Journal
    Cureus.
    Volume/Issue
    16(5)
    [DOI]
    10.7759/cureus.60621.
    [PMID]
    38903282.
    1 citation PubMed Publisher’s Site

  2. Long-term quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate.

    Journal
    Epilepsy & behavior : E&B.
    Volume/Issue
    148
    [DOI]
    10.1016/j.yebeh.2023.109466.
    [PMID]
    37839247.
    PubMed Publisher’s Site

  3. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.

    Journal
    Clinical neurology and neurosurgery.
    Volume/Issue
    225
    [DOI]
    10.1016/j.clineuro.2022.107552.
    [PMID]
    36657359.
    4 citations PubMed Publisher’s Site

  4. Prolonged post-ictal atrial fibrillation following seizures.

    Journal
    Epilepsy & behavior reports.
    Volume/Issue
    16
    [DOI]
    10.1016/j.ebr.2021.100481.
    [PMID]
    34693244.
    3 citations PubMed Publisher’s Site

  5. Adult Presentation of Ornithine Transcarbamylase Deficiency: 2 Illustrative Cases of Phenotypic Variability and Literature Review.

    Journal
    The Neurohospitalist.
    Volume/Issue
    9(1):30-36
    [DOI]
    10.1177/1941874418764817.
    [PMID]
    30671162.
    13 citations PubMed Publisher’s Site

  6. Seizure semiology and aging.

    Journal
    Epilepsy & behavior : E&B.
    Volume/Issue
    20(2):375-7
    [DOI]
    10.1016/j.yebeh.2010.12.033.
    [PMID]
    21273137.
    29 citations PubMed Publisher’s Site

Grants

  1. AN OPEN-LABEL, MULTICENTER, OUTPATIENT EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES

    Active

    Role:
    Principal Investigator
    Funding:
    UCB BIOPHARMA SRL

  2. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES

    Active

    Role:
    Principal Investigator
    Funding:
    UCB BIOPHARMA SRL

  3. AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY

    Role:
    Principal Investigator
    Funding:
    PAREXEL INTERNATIONAL PTY via UCB BIOSCIENCES

  4. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy

    Role:
    Principal Investigator
    Funding:
    NCGS via XENON PHARMACEUTICALS

  5. A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy

    Role:
    Principal Investigator
    Funding:
    PAREXEL INTERNATIONAL PTY via UCB BIOSCIENCES

Education

  1. Epilepsy Fellowship

    Cleveland Clinic Foundation

  2. Clinical Neurophysiology Fellowship

    Oklahoma University Health Sciences Center

  3. Neurology Residency

    Oklahoma University Health Sciences Center

  4. Bachelor of Medicine, Bachelor of Surgery

    University of Mysore

Contact Details

Emails:
Business:
suparna.krishnaiengar@jax.ufl.edu
Addresses:
Business Mailing:
653 W 8TH ST
 JACKSONVILLE FL 32209